Journal Browser

Go Edit a Special Issue


Special Issue Title:

Acute Gout

Deadline for manuscript submissions: 31 October 2021

Print Special Issue Flyer (4)

Special Issue Editor

  • Guest Editor

    Dr. Sombat MuengtaweepongsaE-MailWebsite

    MD, Associate Professor and Associate Dean for Research Affairs, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand

    Interests: Cerebrovascular and Critical care Neurology particularly targeted temperature management and stroke, Acute gout

Special Issue Information

Acute gout remains the most frequent inflammatory arthritis in adults, although gout is a well-known rheumatologic disease. The incidence of acute gout keeps rising. There are still many gaps in the management of gout. Acute gout sometimes occurs during hospitalization with other systemic illnesses. NSAIDS and colchicine are the most frequently used for the treatment of acute gout. However, other anti-inflammatory drugs may also be useful.

The urate-lowering therapy seems not that helpful during an acute gout attack. The role of urate-lowering drugs in acute gout is controversial. Serum urate usually remains normal at the time of acute gout attack. The explanation for this low serum urate phenomenon is still lacking. It is still controversial whether asymptomatic hyperuricemia has any clinical significance. The dilemmas emerge among many previous studies concerning asymptomatic hyperuricemia.

The emerging environmental risk factors for acute gout attacks include particle matter 2.5 (PM 2.5). The relationship between air pollution and gout is still controversial.

This special issue aims to address the unmet needs and dilemmas in acute gout management. Fundamental science research, clinical trials, review articles, correspondence, and case reports are welcome for submission.


Gout, Colchicine, Urate-lowering drugs, Serum urate, Asymptomatic hyperuricemia

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Signa Viate is an international peer-reviewed open access journal published by MRE Press. As of January 2021, Signa Vitae will change to a bimonthly journal. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Published Papers (1 papers)

Open Access Special Issue

Gout flare in the critical care setting: diagnostic challenges and treatment options

Panchalee Satpanich,Kanon Jatuworapruk

DOI: 10.22514/sv.2021.217

(This article belongs to the Special Issue Acute Gout)

Abstract ( 895 ) PDF (848.12 KB) ( 215 ) Full Text

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time